NUP153 Antibody

What is NUP153 and why is it important in cellular research?

NUP153 is a nucleoporin with a molecular weight of approximately 154 kDa that forms an essential component of the nuclear pore complex (NPC) . It plays a critical role in multiple cellular processes including the import of proteins into the nucleus and the export of RNAs and proteins from the nucleus . Research has revealed that NUP153 is uniquely positioned at the nuclear basket of the NPC, making it one of the first components that RNA or proteins encounter during export . NUP153 has gained significant research interest because it is involved in epigenetic regulation and has been implicated in cardiovascular disorders, including dystrophin-deficient cardiomyopathy . Understanding NUP153 function is essential for elucidating the mechanisms of nucleocytoplasmic transport and their dysregulation in disease states.

What are the structural domains of NUP153 and their functions?

NUP153 possesses multiple distinct domains with specialized functions:

• The N-terminal domain is exposed at the nuclear ring of the NPC and is involved in anchoring to the nuclear basket .

• The zinc-finger domain is exposed at the distal ring of the NPC and participates in interactions with transport substrates .

• The C-terminal domain appears to be highly flexible rather than restricted to one particular subdomain of the NPC, suggesting dynamic involvement in transport mechanisms .

This domain organization allows NUP153 to participate in various aspects of nuclear transport, with different domains potentially interacting with different transport cargoes or facilitating different steps in the transport process .

What applications are NUP153 antibodies commonly used for?

NUP153 antibodies are employed in multiple experimental applications as illustrated in the following table:

The selection of appropriate application depends on research objectives and experimental design considerations .

How do domain-specific antibodies reveal the topology of NUP153 within the NPC?

Domain-specific antibodies have been instrumental in elucidating the complex arrangement of NUP153 within the three-dimensional architecture of the nuclear pore complex. Research using antibodies targeting distinct domains of Xenopus NUP153 has revealed that different portions of the protein occupy different spatial locations within the NPC . The N-terminal domain is exposed at the nuclear ring, while the zinc-finger domain localizes to the distal ring of the NPC . Interestingly, the C-terminal domain demonstrates considerable flexibility, not being restricted to any particular subdomain .

This multi-site topology suggests that NUP153 spans across different regions of the NPC, potentially functioning as a molecular bridge in nucleocytoplasmic transport pathways. The research clearly demonstrates that using multiple domain-specific antibodies is essential for understanding the complete spatial arrangement of complex nucleoporins like NUP153, as targeting a single epitope would provide only partial information about protein localization .

What mechanisms explain how anti-NUP153 antibodies block nuclear export?

Studies using microinjection of anti-NUP153 antibodies into oocyte nuclei have provided significant insights into NUP153's role in nucleocytoplasmic transport. These antibodies block the export of three major classes of RNA (snRNA, mRNA, and 5S rRNA) as well as the NES protein export pathway, specifically affecting the HIV Rev protein and Rev-dependent RNA export .

The blocking mechanism appears to be highly specific, as not all export pathways are inhibited - tRNA export and the recycling of importin β to the cytoplasm remain unaffected . This selective inhibition pattern suggests that different export pathways utilize distinct interactions with NUP153, with some paths entirely dependent on NUP153 function while others can bypass it.

The mechanistic basis likely involves the antibodies preventing critical interactions between NUP153 and transport receptors or cargoes. Experimental evidence indicates that NUP153 may directly or indirectly associate with RNA, as demonstrated by its interaction with certain homoribopolymers in vitro . This interaction capability distinguishes NUP153 from other nucleoporins involved in RNA export and provides insight into its unique role in transport pathways.

How does NUP153 contribute to epigenetic regulation in cardiac tissue?

Research on dystrophin-deficient mdx mice (a model for cardiomyopathy) has revealed that NUP153 plays a significant role in epigenetic regulation in cardiac tissue . NUP153 in these mice demonstrates increased protein expression and lysine acetylation, accompanied by enhanced lysine acetyl transferase (KAT) activity . This activity is associated with increased binding to the lysine acetylases P300/CBP-associated factor (PCAF) and p300 .

The functional significance of these modifications was demonstrated through silencing experiments in mdx organotypic heart tissue slices, where NUP153 knockdown caused a reduction in PCAF- and p300-specific activities . Furthermore, the level of nitric oxide (NO), which is reduced in mdx mice, plays an important role in KAT-dependent regulation of NUP153 .

NUP153 is recruited to chromatin and regulates the transcription of genes involved in cardiac remodeling, including the actin-binding protein nexilin . This regulatory function was confirmed when nexilin protein expression was abrogated by NUP153 silencing in mdx organotypic cultures . Additionally, electrophysiological experiments showed that NUP153 overexpression in normal cardiomyocytes increases Cav1.2 calcium channel expression and function .

These findings establish NUP153 as an epigenetic regulator that, under conditions of altered NO signaling, mediates the activation of genes potentially associated with early dystrophic cardiac remodeling.

What are the optimal conditions for using NUP153 antibodies in Western blot applications?

For optimal Western blot results with NUP153 antibodies, researchers should consider the following protocol parameters:

• Dilution Range: Use between 1:500-1:2400 dilution for most commercial NUP153 antibodies, with exact dilution requiring optimization for specific antibody lots and experimental systems .

• Detection System: NUP153 has an observed molecular weight of 154 kDa, so use appropriate molecular weight markers and gel percentage that allows good resolution in this range .

• Sample Preparation: For consistent results, use protein extraction methods that preserve nuclear envelope proteins. Complete protease inhibitor cocktails are recommended to prevent degradation .

• Positive Controls: Validated positive results have been reported in various cell lines including K-562, HeLa, A431, HepG2, and MCF-7 cells .

• Blocking Conditions: Typical blocking with 5% non-fat dry milk or BSA in TBST, but optimization may be necessary depending on the specific antibody formulation.

• Primary Antibody Incubation: Overnight incubation at 4°C often yields the best signal-to-noise ratio for nuclear pore complex proteins.

It is recommended that each antibody be titrated in the specific testing system to obtain optimal results, as sample-dependent variations can significantly impact performance .

How can I validate the specificity of NUP153 antibodies in my experimental system?

Validating antibody specificity is crucial for reliable experimental outcomes. For NUP153 antibodies, consider these validation approaches:

• Western Blot Analysis: Confirm detection of a single band at approximately 154-160 kDa in nuclear extracts. Cross-validation with mAb414 (which recognizes several nucleoporins including NUP153) can provide additional confirmation .

• Immunofluorescence Pattern: Verify the characteristic nuclear rim staining pattern with minimal nucleoplasmic signal, consistent with NPC localization .

• Parallel Testing Methods:

  • Signal-to-noise ratio assessment: Compare staining intensity at the nuclear envelope versus nucleoplasm and cytoplasm (should be >50 times higher at the NE) .

  • Control antibodies: Include isotype-matched control antibodies (e.g., monoclonal human factor VIII antibody has been used as a control) .

• Functional Validation: Consider small-scale functional blocking studies to confirm that the antibody impacts NUP153-dependent processes .

• Species Cross-reactivity Testing: If working across species, verify antibody reactivity as documented cross-reactivity includes human, mouse, rat, and pig models .

• RNA Interference Control: Use siRNA knockdown of NUP153 followed by immunoblotting or immunofluorescence to confirm signal specificity.

What methods can be used to study NUP153's role in RNA export?

To investigate NUP153's function in RNA export, researchers can employ several methodological approaches:

• Antibody Microinjection Studies: Inject anti-NUP153 antibodies into nuclei followed by in situ hybridization with fluorescently labeled antisense probes to visualize the impact on specific RNA export pathways. This method has successfully demonstrated NUP153's differential effects on various RNA classes (mRNA, snRNA, rRNA) .

• RNA-Protein Interaction Assays:

  • Utilize homoribopolymers as sequence-independent probes to assess interactions between NUP153 and RNA molecules .

  • Conduct RNA immunoprecipitation (RIP) assays to identify specific RNA species that associate with NUP153.

• Live-Cell Imaging Approaches:

  • Express fluorescently tagged RNA reporters and monitor their export kinetics after NUP153 manipulation.

  • Combine with photoactivatable or photoconvertible fluorescent proteins to track specific RNA populations.

• Domain-Specific Functional Analysis:

  • Use domain-specific antibodies or expression of truncated NUP153 constructs to determine which domains are critical for different RNA export pathways .

  • Create chimeric proteins to test domain function in a controlled manner.

• Quantitative Export Assays:

  • Measure the nuclear/cytoplasmic distribution of specific RNA species using cellular fractionation followed by RT-qPCR.

  • Employ reporter constructs containing known export elements to quantify export efficiency.

These methodologies provide complementary approaches to dissect the specific mechanisms by which NUP153 facilitates or regulates RNA export through the nuclear pore complex.

How is NUP153 function altered in cardiac disease models?

Research has identified significant alterations in NUP153 expression and post-translational modifications in cardiac disease models. In dystrophin-deficient mdx mice, a model for cardiomyopathy, NUP153 demonstrates:

• Increased protein expression levels compared to controls .

• Enhanced lysine acetylation, with corresponding increases in lysine acetyl transferase (KAT) activity associated with NUP153 .

• Increased binding with the lysine acetylases PCAF and p300 .

• Altered function in response to reduced nitric oxide (NO) levels, a characteristic feature of mdx mice .

Treatment of mdx heart tissue with either an NO donor or the KAT inhibitor anacardic acid normalizes NUP153 protein expression, demonstrating the regulatory role of these pathways . Similar alterations in NUP153 protein expression and intracellular localization were observed in dystrophic cardiomyocytes derived from patient-specific induced pluripotent stem cells .

Importantly, NUP153 up-regulation and increased acetylation were also documented in heart tissue from Duchenne muscular dystrophy patients, validating the translational relevance of the findings from animal models . Recent studies have further revealed a correlation between increased Nup160 and Nup153 protein levels and ventricular function in ischemic cardiomyopathy, suggesting broader implications in various cardiac disorders .

What experimental approaches can be used to study NUP153's role in gene regulation?

To investigate NUP153's involvement in gene regulation, researchers can employ several sophisticated approaches:

• Chromatin Immunoprecipitation (ChIP):

  • Identify genomic regions where NUP153 is recruited to chromatin.

  • Follow with sequencing (ChIP-seq) to generate genome-wide binding profiles.

  • Combine with RNA-seq after NUP153 manipulation to correlate binding with expression changes.

• Epigenetic Modification Analysis:

  • Examine how NUP153 affects histone modifications at target genes.

  • Study the interplay between NUP153 and histone acetyltransferases such as PCAF and p300 .

  • Employ techniques like ChIP-MS (mass spectrometry) to identify protein complexes associated with NUP153 on chromatin.

• Gene Expression Manipulation:

  • Use siRNA or shRNA knockdown of NUP153 in organotypic cultures to assess effects on target gene expression .

  • Perform rescue experiments with wild-type or mutant NUP153 to identify critical domains.

  • Employ CRISPR-Cas9 genome editing for more precise genetic manipulation.

• Protein-Protein Interaction Studies:

  • Investigate interactions between NUP153 and transcription factors or chromatin modifiers.

  • Use proximity labeling techniques (BioID, APEX) to identify nuclear proteins in close proximity to NUP153.

• Target Gene Validation:

  • Focus on specific genes regulated by NUP153, such as nexilin and Cav1.2 calcium channels in cardiac tissue .

  • Use reporter assays to confirm direct transcriptional regulation.

These methodologies can provide mechanistic insights into how a protein traditionally associated with nuclear transport can also function as an epigenetic regulator influencing gene expression in both normal and disease states.

What are common issues when working with NUP153 antibodies and how can they be resolved?

When working with NUP153 antibodies, researchers may encounter several technical challenges. Here are common issues and their solutions:

• High Background in Immunofluorescence:

  • Cause: Insufficient blocking or too high antibody concentration.

  • Solution: Increase blocking time (2+ hours), use alternative blocking agents (BSA, normal serum), and optimize antibody dilution (start with recommended dilution and adjust as needed).

• Multiple Bands in Western Blot:

  • Cause: Protein degradation, cross-reactivity, or post-translational modifications.

  • Solution: Use fresh samples with complete protease inhibitors, increase washing stringency, and validate with positive controls known to express NUP153 (K-562, HeLa, A431, HepG2, or MCF-7 cells) .

• Weak or No Signal:

  • Cause: Inefficient extraction of nuclear envelope proteins or epitope masking.

  • Solution: Use specialized nuclear extraction protocols, consider alternative fixation methods that better preserve the nuclear pore complex structure, and verify antibody storage conditions (most NUP153 antibodies require -20°C storage in buffer containing glycerol) .

• Inconsistent Results Across Experiments:

  • Cause: Antibody degradation or variability in experimental conditions.

  • Solution: Aliquot antibodies to avoid freeze-thaw cycles, standardize protocols, and include positive controls in each experiment for normalization .

• Species Cross-Reactivity Issues:

  • Cause: Epitope differences across species.

  • Solution: Verify the antibody's documented reactivity with your species of interest. Current data indicates reliable reactivity with human, mouse, and rat samples, with some antibodies also recognizing pig NUP153 .

Proper antibody validation and protocol optimization are essential steps before conducting critical experiments with NUP153 antibodies.

How should NUP153 antibodies be stored and handled for optimal performance?

Proper storage and handling of NUP153 antibodies is crucial for maintaining their performance over time:

• Storage Temperature:

  • Store at -20°C as recommended by manufacturers.

  • NUP153 antibodies are typically stable for one year after shipment when stored properly .

• Storage Buffer:

  • Most commercial NUP153 antibodies are supplied in PBS with 0.02% sodium azide and 50% glycerol at pH 7.3 .

  • This formulation helps maintain antibody stability during freeze-thaw cycles.

• Aliquoting Recommendations:

  • For most -20°C storage, aliquoting is not strictly necessary but is still recommended for frequently used antibodies .

  • Smaller size formats (20μl) typically contain 0.1% BSA as an additional stabilizing agent .

• Thawing Protocol:

  • Thaw antibodies completely on ice or at 4°C, never at room temperature.

  • Mix gently by inverting or mild vortexing to ensure homogeneity before use.

• Working Dilution Handling:

  • Prepare working dilutions fresh on the day of use whenever possible.

  • If working dilutions must be stored, keep at 4°C and use within 24-48 hours.

  • Include 0.02-0.05% sodium azide in working dilutions if they must be stored longer.

• Contamination Prevention:

  • Use sterile technique when handling antibody stock solutions.

  • Change pipette tips between aliquot preparations to prevent cross-contamination.

Following these storage and handling recommendations will help ensure consistent antibody performance and extend the useful life of NUP153 antibodies in research applications.